miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance

Siao-Yi Wang; Stephen Shiboski; Cassandra D. Belair; Matthew R. Cooperberg; Jeffrey P. Simko; Hubert Stoppler; Janet Cowan; Peter R. Carroll; Robert Blelloch

doi:10.1371/journal.pone.0098597

Loading metrics

Open Access

Peer-reviewed

Research Article

miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance

Siao-Yi Wang,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Stephen Shiboski,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Cassandra D. Belair,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Matthew R. Cooperberg,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Jeffrey P. Simko,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Hubert Stoppler,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Janet Cowan,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Peter R. Carroll,

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯
Robert Blelloch

* E-mail: blellochr@stemcell.ucsf.edu

Affiliation Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, United States of America
⨯

miR-19, miR-345, miR-519c-5p Serum Levels Predict Adverse Pathology in Prostate Cancer Patients Eligible for Active Surveillance

Siao-Yi Wang,
Stephen Shiboski,
Cassandra D. Belair,
Matthew R. Cooperberg,
Jeffrey P. Simko,
Hubert Stoppler,
Janet Cowan,
Peter R. Carroll,
Robert Blelloch

Published: June 3, 2014
https://doi.org/10.1371/journal.pone.0098597

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

MicroRNAs
Is the Subject Area "MicroRNAs" applicable to this article?

Thanks for your feedback.
Prostate cancer
Is the Subject Area "Prostate cancer" applicable to this article?

Thanks for your feedback.
Biopsy
Is the Subject Area "Biopsy" applicable to this article?

Thanks for your feedback.
Cancer risk factors
Is the Subject Area "Cancer risk factors" applicable to this article?

Thanks for your feedback.
Cancers and neoplasms
Is the Subject Area "Cancers and neoplasms" applicable to this article?

Thanks for your feedback.
Prostate gland
Is the Subject Area "Prostate gland" applicable to this article?

Thanks for your feedback.
In situ hybridization
Is the Subject Area "In situ hybridization" applicable to this article?

Thanks for your feedback.
Surgical pathology
Is the Subject Area "Surgical pathology" applicable to this article?

Thanks for your feedback.